Our Stock of the Week is Definium Therapeutics (DFTX). Definium Therapeutics, formerly known as MindMed (which traded under the ticker MNMD), is a late-stage clinical biopharmaceutical company developing a pharmaceutically optimized form of LSD (DT120, also referred to as lysergide tartrate) as a treatment for generalized anxiety disorder, major depressive disorder, and eventually PTSD. What differentiates DFTX is that it has a mature pipeline with four Phase 3 trials underway and a Solid balance sheet.
Notably, on April 18, 2026, the White House issued a major Executive Order aimed at accelerating mental health innovation and expanding access to psychedelic-based medical treatments for severe mental illness. The order directly addressed clearing regulatory roadblocks and fast-tracking research for therapies targeting the underlying causes of psychiatric conditions. With DFTX already holding a Breakthrough Therapy designation, analysts interpreted this executive order as a major de-risking event for the upcoming Phase 3 readouts, effectively putting the federal government’s weight behind the regulatory pathway the company is on.
To wit, DFTX has three pivotal Phase 3 readouts expected over roughly the next two quarters: the Emerge study in MDD around mid-year, the Voyage study in GAD in early Q3, and the Panorama study in GAD in late Q3. Analysts are optimistic heading into the data, with a consensus Buy rating With an average price target price target near $38. Meanwhile, specialist biotech fund Deep Track Capital recently disclosed a new ownership stake. Of course, it’s worth mentioning that biotechs are often volatile. While it’s always important to have a clear plan for every position, It’s particularly true for positions heading into potentially volatile binary events.
Technically, DFTX has been a solid trender for over a year and has spent the past several weeks carving out a base, with shares pushing toward resistance on an uptick in volume in recent sessions as anticipation builds into the Emerge readout. As always, we will not chase any early strength on Monday morning, but will look to aggressively trade the stock as the chart develops.
Interested in learning about how we help clients build long-term wealth and not end up being a charity to the IRS in the process? Click here to invest with RevShark, and let’s explore the how we can to make a significant impact on your results.
This post is for educational purposes only! This is not advice or a recommendation. We do not give investment advice. Do not act on this post. Do not buy, sell, or trade the stocks mentioned herein. We WILL actively trade this stock differently than discussed herein. We will sell into strength and buy or sell at any time for any reason. We will actively trade into any unusual activity. At the time of this post, principals, employees, and affiliates of Shark Investing, Inc. and/or principals, clients, employees, and affiliates of Hammerhead Financial Strategies, LLC, directly or indirectly, controlled investment and/or trading accounts containing positions in DFTX at the time this was published. To accommodate the objectives of these investing and/or trading accounts, the trading in these shares will be contrary to and/or inconsistent with the information contained in this posting.
